Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Pfizer Inc. NYSE: PFE. In a filing disclosed on April 28th, the Representative disclosed that they had sold between $15,001 and $50,000 in Pfizer stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
- Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
- Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.
- Sold $15,001 - $50,000 in shares of Occidental Petroleum NYSE: OXY on 4/8/2025.
- Sold $1,001 - $15,000 in shares of QUALCOMM NASDAQ: QCOM on 4/8/2025.
- Sold $1,001 - $15,000 in shares of Best Buy NYSE: BBY on 4/8/2025.
- Sold $1,001 - $15,000 in shares of EOG Resources NYSE: EOG on 4/8/2025.
- Sold $1,001 - $15,000 in shares of CSX NASDAQ: CSX on 4/8/2025.
- Sold $1,001 - $15,000 in shares of Valero Energy NYSE: VLO on 4/8/2025.
- Sold $15,001 - $50,000 in shares of Accenture NYSE: ACN on 4/8/2025.
Pfizer Stock Performance
NYSE:PFE traded up $0.31 during trading hours on Friday, reaching $24.24. 22,293,779 shares of the company's stock were exchanged, compared to its average volume of 48,238,230. The company has a 50-day moving average of $24.39 and a 200 day moving average of $25.82. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $137.45 billion, a price-to-earnings ratio of 17.19, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the company posted $0.82 earnings per share. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.10%. Pfizer's dividend payout ratio is presently 124.64%.
Insider Activity
In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.06% of the company's stock.
Analyst Ratings Changes
Several research firms recently issued reports on PFE. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $29.64.
Read Our Latest Research Report on Pfizer
Institutional Trading of Pfizer
Several hedge funds and other institutional investors have recently bought and sold shares of PFE. Woodward Diversified Capital LLC lifted its stake in shares of Pfizer by 7.0% during the 1st quarter. Woodward Diversified Capital LLC now owns 16,564 shares of the biopharmaceutical company's stock worth $420,000 after purchasing an additional 1,082 shares during the period. Concord Wealth Partners increased its stake in Pfizer by 174.2% in the first quarter. Concord Wealth Partners now owns 48,349 shares of the biopharmaceutical company's stock valued at $1,225,000 after purchasing an additional 30,715 shares during the last quarter. Graypoint LLC lifted its position in Pfizer by 3.4% during the first quarter. Graypoint LLC now owns 41,894 shares of the biopharmaceutical company's stock worth $1,062,000 after buying an additional 1,366 shares during the period. Ascent Wealth Partners LLC boosted its stake in Pfizer by 1.4% in the 1st quarter. Ascent Wealth Partners LLC now owns 76,627 shares of the biopharmaceutical company's stock worth $1,942,000 after buying an additional 1,039 shares during the last quarter. Finally, Verdence Capital Advisors LLC grew its holdings in Pfizer by 9.8% in the 1st quarter. Verdence Capital Advisors LLC now owns 124,794 shares of the biopharmaceutical company's stock valued at $3,162,000 after buying an additional 11,154 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
